Aldevron is "Driven by a Passion to Enable Science," as featured in the April Genetic Engineering & Biotechnology News. This article spans our new production facility in Fargo, North Dakota, and the expansion of our Freiburg, Germany, antibody facility, to our expanding CRISPR options, the publication discusses our ongoing push to help researchers in their work.
One particular highlight is the discussion of our new CRISPR options, including GMP level SpyFiTM Cas9 Nuclease and the availability of in-stock GMP level prepacked CRISPR nucleases.
Andy Rodgers has joined Aldevron as its Director of Operational Excellence. In his position, Rodgers will be responsible for developing, implementing and managing strategies and objectives to ensure the achievement of the company’s goals to improve performance, quality, delivery and cost.
Lance Monilaws of Aldevron has been promoted as its Director of Industrial Project Management. In his position, Monilaws will direct large capital projects with emphasis in facility expansion, renovation and campus planning. He will also manage various operational initiatives and strategies, including but not limited to construction and industrial technology.
Ally Hauser of Aldevron has been promoted to Director of Client Relations for Protein Services. In her position, Hauser will lead new projects and initiatives to expand research grade and cGMP protein services to the benefit of our clients.
Reported by Patrick Springer of the Forum of Fargo-Moorhead
Tom Foti, Vice President and General Manager of Aldevron's Madison site, discussed the addition of a 1,000 liter fermentor and significant expansion of the site's manufacturing space at the American Society of Gene & Cell Therapy conference in Washington, DC.
Aldevron announced today its new fermentation capacity of 1,000 liters and plans to significantly increase the Company’s manufacturing footprint in Madison, WI. The large-scale fermentation equipment is already installed and will be coming on-line in Q4 2019.
James Brown, Ph.D., presenting "Standardized Plasmids for Viral Vector Production" tech talk at American Society of Gene & Cell Therapy Annual Meeting
Representatives from Aldevron will attend the 22nd Annual Meeting for the American Society of Gene & Cell Therapy (ASGCT), April 29 - May 2, 2019, in Washington, D.C.
Dr. Victoria Sowemimo has joined Aldevron as its new Director of Quality Assurance. In her position, Sowemimo will lead the company’s cGMP Quality Assurance functions supporting through all phases of clinical and commercial product release, management of Aldevron’s quality systems and regulatory training to assure compliance to all phase appropriate requirements pertaining to Good Manufacturing Practices.